That's not what I heard. It seems he is pulling th

That's not what I heard. It seems he is pulling the classic GC move. Originally we were going to complete a transaction for the DX division this summer. In the years first CC they actually said they delayed the closing of ESS due to the fact they believed non dilutive funds from this transaction would allow them to do so with out dilution. Obviously this did not materialize. In his last presentation he says he expects "at least one transaction this quarter" Im guessing Lympro agreement with AVXL something small. Listen again it definitely does not sound like a DX div transaction. Also it is clear to anyone with 2 brain cells Lympro is simply not there. That's not bashing just deductive reasoning. Will it get there? Perhaps but not ready for BP trial use or imo a BP sale. He definitely is not giving a timeline for up list currently bc he knows he cant commit to one. I highly doubt Nasdaq this quarter. Lets hope ESS pans out in next 6 months otherwise those new shares will heavily be used to further dilute us. Especially considering ELTO data in early 2016 was supposed to be a MAJOR catalyst. A partner in 2016 was mentioned in all previous presentations.